Radiation proctitis (RP) is a significant unmet medical need, with no well-established standard of care. Access is actively seeking marketing partners globally for ProctiGard™.
Access Pharmaceuticals president and CEO Jeffrey B. Davis noted that the company is actively developing follow-on products to MuGard that leverage its powerful mucoadhesive polymer hydrogel drug delivery technology, and ProctiGard is the first example of this development effort.
"Radiation proctitis is a condition somewhat analogous to oral mucositis, concerning the damage and ulceration of the mucosal tissue of the digestive tract. The development of ProctiGard™ is a direct response to dialogue with the oncology community that is looking for better, more effective treatment options for this debilitating oncology side effect.
"Access intends to follow the MuGard® development and commercialization strategy with ProctiGard™ by progressing manufacturing scale-up, the signing of multiple commercialization partners here in the US and abroad, and the completion and successful publication of supportive, positive clinical data similar to the recently published MuGard® clinical trial data in Cancer," Davis added.